Icoria Receives Notice of Allowance on Tissue Analysis Patent
News Sep 30, 2005
Icoria, Inc. has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application related to the high throughput measurement of blood vessels in a tissue sample.
This recently allowed patent application is a part of the portfolio of issued and pending patents that Icoria purchased in 2004 in the acquisition of TissueInformatics.Inc.
The allowed patent application, entitled “Methods for Quantitative Analysis of Blood Vessel Structure,” is drawn to cover the methods of geometrical analysis that enable the automated measurement of several features of images of tissue.
These methods allow fast, repeatable and accurate analysis of tissue samples.
The proof-of-concept work underlying the application involved a cardiovascular device study in an animal model of the restenosis-like response of blood vessels injured by balloon angioplasty.
Possible applications for the technology include the cardiovascular device market.
“Quantitative tissue analysis represents an important advance in characterizing disease progression and, as in the proof-of-concept work here, potential therapeutic outcomes,” said Thomas Colatsky, Chief Scientific Officer and Vice President of Research.
“Our growing portfolio of patents covering methods of quantitative tissue analysis not only supports our internal capabilities in biomarker discovery, but may also represent a potential licensing opportunity for companies requiring new ways of extracting high content biological image data for clinical and preclinical research.”
Icoria has four issued U.S. patents and thirteen U.S. and international patent applications in its quantitative tissue analysis portfolio.
The company has a total of 70 pending U.S. patent applications, 42 pending international patent applications, and 24 issued U.S. patents.
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE